LOS ANGELES–( BUSINESS WIRE )– Lundin Law PC , a shareholder rights firm, announces the filing of a class action lawsuit against Dynavax Technologies Corporation (“Dynavax” or the “Company”) (Nasdaq: DVAX) concerning possible violations of federal securities laws between March 10, 2014 and November 11, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm in advance of the January 17, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here . You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected] .

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Dynavax made false and/or misleading statements and/or failed to disclose: that the phase 3 HBV-23 trial for the Company’s lead vaccine product HEPLISAV-B was not designed in accordance with the U.S. Food and Drug Administration’s concerns and issues; that the Company failed to provide sufficient information to the FDA in its Revised Biologics License Application for the drug; that Dynavax’s resources will not be sufficient for the Company to advance the HEPLISAV-B program on its own; and that as a result of the above, the Company’s financial statements and statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On November 14, 2016, Dynavax announced that it received a Complete Response Letter from the U.S. Food and Drug Administration requesting additional information on the Company’s HEPLISAV-B product in connection with its Biologics License Application.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholder.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.